overall survival phenotype

Aliases

OS

Related entities (2)

Mentioned in (100)

Papers in which this entity is mentioned.

• Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis. (2026)
• Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types. (2026)
• Whole-genome landscapes of 1,364 breast cancers. (2026)
• Chromosomal instability as a driver of cancer progression. (2025)
• Functional analysis of cancer-associated germline risk variants. (2025)
• Tracing the evolution of single-cell 3D genomes in Kras-driven cancers. (2025)
• Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. (2024)
• Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. (2024)
• Transient loss of Polycomb components induces an epigenetic cancer fate. (2024)
• The landscape of drug sensitivity and resistance in sarcoma. (2024)
• Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. (2024)
• Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. (2023)
• A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns. (2023)
• Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. (2023)
• Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients (2023)
• Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. (2023)
• Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. (2023)
• Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors. (2023)
• Towards understandings of serine/arginine-rich splicing factors. (2023)
• RNA splicing dysregulation and the hallmarks of cancer. (2023)
• Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. (2022)
• Explainable multiview framework for dissecting spatial relationships from highly multiplexed data. (2022)
• Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. (2022)
• Embryonic Nicotine Exposure Disrupts Adult Social Behavior and Craniofacial Development in Zebrafish. (2022)
• Inferring gene expression from cell-free DNA fragmentation profiles. (2022)
• Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. (2022)
• Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. (2022)
• Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. (2022)
• Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. (2021)
• Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. (2021)
• Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. (2021)
• A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. (2021)
• Detection and characterization of lung cancer using cell-free DNA fragmentomes. (2021)
• Biologically informed deep neural network for prostate cancer discovery. (2021)
• Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. (2021)
• B cells and tertiary lymphoid structures promote immunotherapy response. (2020)
• Immuno-genomic landscape of osteosarcoma. (2020)
• Inferring structural variant cancer cell fraction. (2020)
• Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. (2020)
• Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. (2020)
• Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. (2020)
• Neoadjuvant checkpoint blockade for cancer immunotherapy. (2020)
• Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures. (2020)
• Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. (2020)
• Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. (2019)
• Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. (2019)
• Determining cell type abundance and expression from bulk tissues with digital cytometry. (2019)
• Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. (2019)
• Differentially sensitive neuronal subpopulations in the central nervous system and the formation of hindbrain heterotopias in ethanol-exposed zebrafish. (2019)
• Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. (2019)
• Genome-Informed Targeted Therapy for Osteosarcoma. (2019)
• Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. (2019)
• Comprehensive analysis of structural variants in breast cancer genomes using single molecule sequencing (2019)
• Pan-cancer whole-genome analyses of metastatic solid tumours. (2019)
• Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. (2018)
• Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. (2018)
• Genome doubling shapes the evolution and prognosis of advanced cancers. (2018)
• Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. (2018)
• The Immune Landscape of Cancer. (2018)
• Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. (2018)
• Profiling Tumor Infiltrating Immune Cells with CIBERSORT. (2018)
• Tumor fraction in cell-free DNA as a biomarker in prostate cancer. (2018)
• EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. (2018)
• Copy number signatures and mutational processes in ovarian carcinoma. (2018)
• SVclone: inferring structural variant cancer cell fraction (2017)
• Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. (2017)
• Integrative clustering of multi-level 'omic data based on non-negative matrix factorization algorithm. (2017)
• Orthotopic patient-derived xenografts of paediatric solid tumours. (2017)
• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. (2017)
• Copy-number signatures and mutational processes in ovarian carcinoma (2017)
• Comprehensive Analysis of Hypermutation in Human Cancer. (2017)
• Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. (2016)
• Landscape of somatic mutations in 560 breast cancer whole-genome sequences. (2016)
• Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. (2016)
• Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. (2016)
• Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
• Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. (2016)
• The Genetics of Fetal Alcohol Spectrum Disorders. (2016)
• Prognostic value of inflammation-based scores in patients with osteosarcoma. (2016)
• A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. (2015)
• BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. (2015)
• Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. (2015)
• Comprehensive genomic profiles of small cell lung cancer. (2015)
• Genome-wide analysis of noncoding regulatory mutations in cancer. (2014)
• CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. (2014)
• Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. (2014)
• Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. (2014)
• Clonal evolution in hematological malignancies and therapeutic implications. (2014)
• The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. (2014)
• Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. (2013)
• Pdgfra protects against ethanol-induced craniofacial defects in a zebrafish model of FASD. (2013)
• An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. (2012)
• Myeloid cells in tumor inflammation. (2012)
• Longevity candidate genes and their association with personality traits in the elderly. (2012)
• Microsatellites with macro-influence in ewing sarcoma. (2012)
• Outlier-Based Differential Expression Analysis in Proteomics Studies. (2011)
• Allele-specific copy number analysis of tumors. (2010)
• Recurring mutations found by sequencing an acute myeloid leukemia genome. (2009)
• Brain signatures of monetary loss and gain: outcome-related potentials in a single outcome gambling task. (2009)
• The HLA system: genetics, immunology, clinical testing, and clinical implications. (2007)

Merged raw entities (3)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.